As an explanation for the greater activity of N-terminal Hsp90 inhibitors against cancers compared to normal tissues, it has been reported that Hsp90 in cancer cells resides predominantly in an activated hetero-complex form with higher inhibitor affinity44,45. This evidence concerns the gene HSP90AB1 and cancer.